ORIGINAL ARTICLE |
|
Year : 2013 | Volume
: 19
| Issue : 2 | Page : 251-258 |
|
Comparison of in-vitro and in-vivo response to fetal hemoglobin production and γ-mRNA expression by hydroxyurea in Hemoglobinopathies
Khushnooma Italia1, Farah Jijina2, Rashid Merchant3, Suchitra Swaminathan1, Anita Nadkarni1, Maya Gupta1, Kanjaksha Ghosh1, Roshan Colah1
1 National Institute of Immunohematology, Hematogenetics, 13th Floor, K.E.M. Hospital Campus, Parel, Mumbai, India 2 Department of Hematology, 10th Floor, K.E.M. Hospital, Parel, Mumbai, India 3 Department of Pediatrics, Nanavati Hospital, Vileparle (W), Mumbai, India
Correspondence Address:
Roshan Colah National Institute of Immunohematology, 13th Floor, N. M. S. Bldg, K.E.M. Hospital Campus, Parel, Mumbai - 400 012 India
![Login to access the Email id](http://www.medknow.com/images/email.gif) Source of Support: None, Conflict of Interest: None
PMID: 24019630 ![Get Permissions](http://www.medknow.com/journals/images/gp.gif)
|
|
Background: Hydroxyurea, which induces Fetal hemoglobin (HbF) synthesis, is the only drug widely used in different hemoglobinopathies; however, the response is very variable. We compared the efficacy of hydroxyurea in-vitro in erythroid cultures and in-vivo in the same patients with different hemoglobinopathies to induce HbF production and enhance γ-messenger RNA expression.
Materials and Methods: A total of 24-patients with different Hemoglobinopathies were given hydroxyurea and their response was studied in-vivo and in-vitro on mononuclear cells collected from them simultaneously.
Results: A total of 57.7% of patients (responders) showed no further crisis or transfusion requirements after hydroxyurea therapy with a mean increase in fetal cells (F-cells) of 63.8 ± 59.1% and γ-mRNA expression of 205.5 ± 120.8%. In-vitro results also showed a mean increase in F-cells of 27.2 ± 24.7% and γ-mRNA expression of 119.6% ± 65.4% among the treated cells. Nearly 19.0% of the partial-responders reduced their transfusion requirements by 50% with a mean increase in F-cells of 61.2 ± 25.0% and 28.4 ± 25.3% and γ-mRNA-expression of 21.0% ± 1.4% and 80.0% ± 14.1% in-vivo and in-vitro respectively. The non-responders (15.3%) showed no change in their clinical status and there was no significant increase in F-cells levels and γ-mRNA expression in-vivo or in-vitro.
Conclusion: Thus, this method may help to predict the in-vivo response to hydroxyurea therapy; however, a much larger study is required. |
|
|
|
[FULL TEXT] [PDF]* |
|
![Email this article](/ServeContent?url=http%3A%2F%2Fwww.ijhg.com%2Ftemplates%2Ficon_mail.gif) |
|